Peptide questions · Eloralintide
Eloralintide side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for eloralintide are nausea, fatigue and constipation, among 8 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: eloralintide has no label: it is still in trials.
What is commonly reported with eloralintide
- Nausea
- Fatigue
- Constipation
- Diarrhea
- Vomiting
- Decreased appetite
- Hair thinning
- Injection site reaction
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Fatigue | 7: Semaglutide, Tirzepatide, Retatrutide, Dulaglutide and 3 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Decreased appetite | 9: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 5 more |
| Hair thinning | None: listed for Eloralintide alone |
| Injection site reaction | 1: Mazdutide |

Model. Individual results vary.
Which eloralintide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Eloralintide shares 7 of its 8 listed effects with at least one other metabolic & GLP-1 compound; hair thinning is listed for eloralintide alone.
What the eloralintide safety notes say
The library’s safety note
Eloralintide has no label: it is still in trials. In the 48-week phase 2 trial, nausea affected 11% on 1 mg and 13% on 3 mg (about the same as 14% on placebo), and 25% to 64% on the higher doses; fatigue rose with dose to 43% to 46% at 9 mg vs 12% on placebo. Most of these were mild to moderate, and Lilly reported fewer of them with a slower step-up. The trial's posted results also list a slower heart rate (bradycardia) in a few people on 6 and 9 mg and none on placebo, and hair thinning in about 1 in 9 on 9 mg (6 of 54) and none on placebo. In Lilly's later trial in type 2 diabetes, 0% to 10.8% on eloralintide alone stopped for side effects. Long-term safety is not yet known. These are trial findings to review with your clinician.
The library’s interaction note
No interaction studies have been published. In the phase 1 trial, eloralintide slowed stomach emptying only a little after the first dose, and the effect faded with weekly dosing, so the authors expect less delay to oral medicines than with older amylin drugs; this still needs confirming. It is not a GLP-1, and Lilly is testing it on top of tirzepatide (EloraTZP), but the GI side effects add up in the pair. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the eloralintide reports come from
The library rates the evidence on eloralintide as moderate: animal studies plus some human data.
Of the library’s 8 research notes on eloralintide, 6 rest on randomized trials and 2 on clinical data.
Our 2 study pages on eloralintide: 2 randomized trials.
So eloralintide has controlled trials in people to set its listed effects against.
What our eloralintide study pages report on safety
Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1
Randomized trial, human, 2026: Appetite loss was the side effect seen most often, in 19% of people on the drug; others included COVID-19 (11%), fatigue (11%) and headache (12%), and most side effects were mild. Gut problems were less frequent, with vomiting in 4%, nausea in 8% and diarrhea in 10%.
Eloralintide: -4.4% body weight at week 4 in a single-dose trial
Randomized trial, human, 2025: In the human trial, participants on eloralintide reported 16 adverse events, and 15 of the 16 were mild; there were 4 gastrointestinal events, including one moderate vomiting event. The human part was a small phase 1 safety trial of single doses in healthy people, with weight checked at week 4, so it does not show long-term weight loss or safety in people with obesity.
Questions people ask
What are the side effects of eloralintide?
The side effects most commonly reported for eloralintide are nausea, fatigue and constipation, among 8 the library lists; the library’s evidence on it includes controlled trials in people.
Do eloralintide’s side effects come from human studies?
The library rates the evidence on eloralintide as moderate, and the library’s evidence on it includes controlled trials in people.
Which eloralintide side effects are its own?
Among the metabolic & GLP-1 compounds, the library lists hair thinning for eloralintide alone.
Does eloralintide interact with other medicines?
The library’s interaction note on eloralintide begins: No interaction studies have been published.